Cellectar Biosciences Inc’s (CLRB) Stock: A Week-by-Week Analysis

In the past week, CLRB stock has gone up by 3.10%, with a monthly decline of -5.00% and a quarterly surge of 44.04%. The volatility ratio for the week is 7.45%, and the volatility levels for the last 30 days are 7.17% for Cellectar Biosciences Inc The simple moving average for the past 20 days is 4.73% for CLRB’s stock, with a 51.20% simple moving average for the past 200 days.

Is It Worth Investing in Cellectar Biosciences Inc (NASDAQ: CLRB) Right Now?

The 36-month beta value for CLRB is at 0.94. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for CLRB is 11.13M, and currently, shorts hold a 16.93% of that float. The average trading volume for CLRB on April 03, 2024 was 1.87M shares.

CLRB) stock’s latest price update

The stock price of Cellectar Biosciences Inc (NASDAQ: CLRB) has surged by 1.79 when compared to previous closing price of 3.92, but the company has seen a 3.10% gain in its stock price over the last five trading sessions. Seeking Alpha reported 2024-03-27 that Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript

Analysts’ Opinion of CLRB

ROTH Capital, on the other hand, stated in their research note that they expect to see CLRB reach a price target of $10. The rating they have provided for CLRB stocks is “Buy” according to the report published on January 21st, 2020.

CLRB Trading at 7.78% from the 50-Day Moving Average

After a stumble in the market that brought CLRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.34% of loss for the given period.

Volatility was left at 7.17%, however, over the last 30 days, the volatility rate increased by 7.45%, as shares sank -5.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.66% upper at present.

During the last 5 trading sessions, CLRB rose by +3.10%, which changed the moving average for the period of 200-days by +90.91% in comparison to the 20-day moving average, which settled at $3.80. In addition, Cellectar Biosciences Inc saw 44.04% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for CLRB

Current profitability levels for the company are sitting at:

  • -117.93 for the present operating margin
  • 0.29 for the gross margin

The net margin for Cellectar Biosciences Inc stands at -114.6. The total capital return value is set at 45.2. Equity return is now at value -536.81, with -225.65 for asset returns.

Based on Cellectar Biosciences Inc (CLRB), the company’s capital structure generated -0.69 points at debt to capital in total, while cash flow to debt ratio is standing at -58.55.

Currently, EBITDA for the company is -38.77 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 121.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.81.

Conclusion

In conclusion, Cellectar Biosciences Inc (CLRB) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts